Loading
A phase 2 trial in lung cancer, run by The First Affiliated Hospital of Zhengzhou University, now recruiting.
MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC is a phase 2, randomised interventional study registered as NCT05286957 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 60 participants, started 2022-06-20 and due to reach its primary completion in 2026-06-01. Interventions recorded: adjuvant tislelizumab and chemotherapy for MRD+ patients; adjuvant tislelizumab and chemotherapy for MRD+ patients; adjuvant chemotherapy for MRD- patients. Conditions listed: NSCLC. Primary outcome: 2-year PFS rate. Lung eligibility wording from the registry: "Histologically confirmed primary NSCLC, postoperative stage is IIA, IIB, IIIA or T3N2IIIB". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/